3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
5
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Osteosarcoma
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Pathologic Complete Response
1
Neutropenia
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Myelosuppression
1
Lung Neoplasms
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Advanced Squamous Non-Small-Cell Lung Cancer
1
Interventions
Paclitaxel
7
Doxorubicin
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
Bevacizumab
4
durvalumab
3
Radiotherapy
3
Propranolol
3
Docetaxel
3
regorafenib
2
cemiplimab
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Nivolumab
2
Ifosfamide
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trebananib
1
trastuzumab duocarmazine
1
talimogene laherparepvec
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hemangiosarcoma
×
trilaciclib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled